Long-term data help two drugs sway ICER in drug price report

An analysis by the Institute for Clinical and Economic Review of price increases for some of the costliest drugs in the U.S. has found that seven of nine were not supported by new clinical evidence, resulting in what ICER called an unjustified increase in total drug spending of $5.1 billion over two years.

While ICER deemed long-term data from multiple myeloma drug Revlimid and HIV therapy Genovya supported price increases for those drugs, seven of the other costliest drugs failed to meet that standard. ...